Tirzepatide and Semaglutide Lead All Weight-Loss Drugs in Landmark Meta-Analysis
A 56-trial network meta-analysis of 60,307 adults ranks every approved obesity drug on weight loss and complication outcomes.
Summary
A systematic review and network meta-analysis published in Nature Medicine evaluated six approved obesity medications across 56 randomized controlled trials enrolling over 60,000 adults. Tirzepatide and semaglutide produced the greatest total body weight loss—16.2% and 11.9% beyond placebo, respectively—far outpacing orlistat (3.1%), naltrexone/bupropion (4.8%), liraglutide (4.5%), and phentermine/topiramate (8.8%). Beyond weight, tirzepatide demonstrated remission of obstructive sleep apnea and metabolic-dysfunction-associated steatohepatitis, while semaglutide reduced major adverse cardiovascular events and knee osteoarthritis pain. All six medications were significantly better than placebo. The findings directly informed the European Association for the Study of Obesity's first GRADE-based treatment algorithm for pharmacological obesity management.
Detailed Summary
Obesity now affects hundreds of millions of adults worldwide, and by 2030 an estimated three billion people will live with overweight or obesity. Lifestyle intervention alone rarely produces durable weight loss because the body actively resists fat loss through hormonal and metabolic counter-regulation. Pharmacological support is therefore increasingly recognized as a necessary component of obesity care, yet head-to-head drug comparisons remain rare, making comparative effectiveness difficult to judge. This meta-analysis was designed to fill that gap and to underpin the first GRADE-based obesity pharmacotherapy algorithm from the European Association for the Study of Obesity.
Researchers searched Medline and Embase through January 31, 2025, identifying 56 placebo-controlled RCTs (60 comparisons) covering six approved obesity management medications (OMMs): orlistat, liraglutide, naltrexone/bupropion, phentermine/topiramate, semaglutide, and tirzepatide. The 60,307 enrolled adults (32,598 on active drug, 27,709 on placebo) had a mean baseline BMI above 30 kg/m². The primary endpoint was percentage total body weight loss (TBWL%) at end of study; secondary endpoints included lipid profiles, blood pressure, HbA1c, fasting glucose, cardiovascular morbidity and mortality, mental health, quality of life, and remission of obesity-related complications.
All six OMMs produced significantly greater TBWL% than placebo. Tirzepatide led with a placebo-subtracted TBWL of 16.2% (95% CI 11.2–21.3%), followed by semaglutide at 11.9% (8.1–15.7%), phentermine/topiramate at 8.8% (8.2–9.5%), naltrexone/bupropion at 4.8% (3.7–5.8%), liraglutide at 4.5% (1.0–7.9%), and orlistat at 3.1% (0.7–5.5%). The two available head-to-head trials confirmed these rankings: liraglutide beat orlistat by 3.8 percentage points and semaglutide beat liraglutide by 9.4 percentage points. Tirzepatide and semaglutide also showed normoglycemia restoration, type 2 diabetes remission, and reduced hospitalizations for heart failure. Semaglutide uniquely demonstrated reduction in major adverse cardiovascular events (MACE) and knee osteoarthritis pain. Tirzepatide uniquely demonstrated remission of obstructive sleep apnea syndrome and metabolic dysfunction-associated steatohepatitis (MASH).
The clinical implications are substantial. The magnitude of weight loss achieved with tirzepatide and semaglutide approaches that historically associated with bariatric surgery in some patients, while also delivering organ-specific benefits that extend beyond the scale. The divergent complication profiles of each drug suggest that treatment choice should be individualized based on a patient's predominant comorbidities rather than weight loss alone—an approach now formalized in the EASO algorithm this NMA was designed to support.
Important caveats apply. Only two direct head-to-head RCTs existed at the time of the search, meaning most comparative estimates rely on indirect network comparisons that carry additional uncertainty. Study quality was heterogeneous (66% double-blind; 29% had reporting issues around allocation or blinding). Long-term safety data beyond two years remain limited for newer agents, and no included trial had a mean baseline BMI below 30 kg/m², limiting generalizability to lower-BMI populations.
Key Findings
- Tirzepatide produced 16.2% greater body weight loss than placebo—the highest of any approved obesity drug.
- Semaglutide reduced major adverse cardiovascular events and knee osteoarthritis pain beyond weight loss.
- Tirzepatide achieved remission of obstructive sleep apnea and MASH in clinical trials.
- Both tirzepatide and semaglutide restored normoglycemia and induced type 2 diabetes remission.
- All six approved obesity medications significantly outperformed placebo for total body weight loss.
Methodology
Systematic review and frequentist network meta-analysis of 56 RCTs (60 comparisons) from Medline and Embase through January 2025, covering 60,307 adults on six approved OMMs versus placebo or active comparator. Primary endpoint was TBWL% at study end; secondary endpoints included metabolic, cardiovascular, and quality-of-life outcomes. Study quality was assessed using Cochrane risk-of-bias criteria.
Study Limitations
Indirect comparisons dominate the network because only two head-to-head RCTs existed, introducing additional uncertainty in relative rankings. Study quality was variable, with nearly 30% of trials having inadequate reporting of allocation concealment or blinding. Long-term safety data beyond two years are sparse for tirzepatide and semaglutide, and all trials enrolled adults with BMI ≥30 kg/m², limiting applicability to lower-weight individuals.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: